Single-agent immunotherapy has achieved limited clinical benefit to date in patients with pancreatic ductal adenocarcinoma (PDAC). This may be a result of the presence of a uniquely immunosuppressive tumor microenvironment (TME). Critical obstacles to immunotherapy in PDAC tumors include a high number of tumor-associated immunosuppressive cells and a uniquely desmoplastic stroma that functions as a barrier to T cell infiltration. We identified hyperactivated focal adhesion kinase (FAK) activity in neoplastic PDAC cells as an important regulator of the fibrotic and immunosuppressive TME. We found that FAK activity was elevated in human PDAC tissues and correlated with high levels of fibrosis and poor CD8 + cytotoxic T cell infiltration. Single-agent FAK inhibition using the selective FAK inhibitor VS-4718 substantially limited tumor progression, resulting in a doubling of survival in the p48-Cre;LSL-Kras G12D ;Trp53 flox/+ (KPC) mouse model of human PDAC. This delay in tumor progression was associated with markedly reduced tumor fibrosis and decreased numbers of tumor-infiltrating immunosuppressive cells. We also found that FAK inhibition rendered the previously unresponsive KPC mouse model responsive to T cell immunotherapy and PD-1 antagonists. These data suggest that FAK inhibition increases immune surveillance by overcoming the fibrotic and immunosuppressive PDAC TME and renders tumors responsive to immunotherapy. npg
a r t i c l e s
The application of immunotherapy holds great promise for improving pancreatic cancer patient outcomes, as it has already done for patients with melanoma or lung cancer. Unfortunately, to date, attempts at immunotherapy in PDAC have achieved limited clinical benefits when deployed as single agents 1 . This is likely a result in part of the presence of a uniquely immunosuppressive TME that is dominant in most human PDACs. This immunosuppressive TME is an important regulator of disease progression and poor responses to conventional therapy. Major drivers of this pro-tumorigenic microenvironment include a highly fibrotic stroma and extensive infiltration by immunosuppressive cell populations [2] [3] [4] [5] [6] [7] . High stromal density can provide a barrier to the delivery of cytotoxic agents and has been postulated to limit T cell access to tumor cells and function once recruited in the tumor site [8] [9] [10] [11] . In addition, extensive myeloid cell infiltration, typical of PDAC, may further lead to the dysfunction of PDAC-infiltrating T cells 2, 4, 6, 12, 13 . Thus, agents that can overcome excessive fibrosis to alter immune suppression would be particularly attractive therapeutics for PDAC.
FAKs are nonreceptor tyrosine kinases, which include FAK1 and PYK2 (also known as FAK2). Of these, FAK1 has been heavily studied in the context of cancer cell migration, proliferation, and survival (reviewed in refs. 14, 15) . Several studies have demonstrated that elevated FAK1 expression enhances tumor malignancy and correlates with poor prognosis 14 . More recently, FAK1 has been implicated in regulating pro-inflammatory pathway activation and cytokine production 15, 16 . In addition, FAK signaling has been implicated in wound healing and/or pathologic fibrosis in several tissues [17] [18] [19] [20] [21] [22] [23] [24] [25] . Because of the role of FAK in translating signals from extracellular matrix composition and/or stiffness into intracellular pro-inflammatory pathway regulation, it seems plausible that FAK might be important for regulating the fibrotic PDAC TME 25 . We sought to determine the effect of FAK signaling in maintaining the fibrotic and immunosuppressive TME of PDAC. We found that FAK1 is a central driver of the fibrotic and immunosuppressive microenvironment that protects tumors from immune surveillance and drives resistance to immunotherapy.
RESULTS

FAK is hyperactivated in human PDAC and correlates with immunosuppressive TMEs
To evaluate whether FAK activation might affect the TME, we analyzed human PDAC tumor tissues for the expression of total and phosphorylated FAK1 (Tyr-397, p-FAK1) and PYK2 (FAK2) by immunohistochemistry (IHC). We found that both total FAK1 and p-FAK1 were upregulated as compared to that in normal pancreatic tissue in 80% (45 of 56) and 84% (47 of 56) of patients, respectively ( Fig. 1a and Supplementary Fig. 1a,b) . IHC also revealed that, although stromal cells had detectable expression of both total FAK1 and p-FAK1 relative to those in control stains, PDAC neoplastic cells expressed far higher levels of total FAK1 and p-FAK1.
To determine whether high levels of FAK1 activation in PDAC cells correlate with changes in the TME, we stratified human PDAC patients on the basis of high or low epithelial (tumor cell) p-FAK1 levels using mean IHC intensity. We found that high p-FAK1 levels in tumor cells were associated with lower numbers of tumor-infiltrating CD8 + cytotoxic T lymphocytes (CTLs), and higher prevalence of both neutrophil elastase + (NE + ) and CD15 + granulocytes ( Fig. 1b  and Supplementary Fig. 1c ). On the basis of the inverse correlation between p-FAK levels and tumor infiltration by CD8 + CTLs, we analyzed the association of this with patient survival and found that high p-FAK1 and low CD8 + CTL levels were indicative of poor clinical outcomes ( Fig. 1c and Supplementary Fig. 1c,d) . To determine how FAK1 activation correlates specifically with tumor fibrosis, we analyzed both total collagen amounts by Sirius Red staining and collagen I, III and IV deposition by IHC. Although the majority of samples showed high levels of fibrosis, we found that tumors with high p-FAK1 expression also had higher levels of total stromal collagen and collagen I deposition ( Fig. 1d,e and Supplementary Fig. 1e ). We found that the extent of collagen I deposition, but not of collagen III or collagen IV deposition, correlated with the amount of p-FAK expression (r = 0.299, P = 0.028, n = 50). Taken together, these data suggest that high levels of tumor FAK1 activation are indicative of a fibrotic and immunosuppressive TME.
To determine the stage of tumor progression at which FAK1 becomes hyperactivated and how this correlates with changes in the TME, we analyzed p-FAK1 expression in pancreatic tissue from the KPC mouse model ( Fig. 1f) . We found that p-FAK1 was barely detectable in the normal pancreatic epithelium and early pancreatic intraepithelial neoplasia lesions (PanIN). However, p-FAK1 levels were modestly upregulated in late PanINs and substantially elevated in PDAC lesions. The absence of FAK hyperactivation in early-stage PanIN lesions suggests that, in contrast with recent reports in mouse models of lung cancer 26 , Kras G12D expression alone is not sufficient to induce FAK activation. Consistent with this, we found that neither the overexpression of Kras G12V in human pancreatic epithelial cells (PDECs) nor the knockdown of Kras in KPC-derived tumor cells (KP cells) led to alterations in total FAK1 or p-FAK1 expression ( Supplementary Fig. 2a,b) . In contrast, we found that matrix stiffness or increased density of collagen I, collagen IV or fibronectin, but not laminin, resulted in elevated FAK activation ( Fig. 1g and Supplementary Fig. 2c-f ). We also observed that the induction of p-FAK1 by collagen density was Rho-associated coiled-coil kinase (ROCK) dependent ( Fig. 1h) . These data are also consistent with observations from several other research groups that collagen density or stiffness can lead to FAK activation in other normal and malignant cell types [27] [28] [29] [30] . Following analysis of the TME present when FAK1 is hyperactivated in KPC mice, we found that p-FAK1 expression is high in PDAC lesions that have extensive collagen deposition and tumorinfiltration by inflammatory cells (F4/80 + and GR1 + ), but few CD8 + CTLs ( Fig. 1f and Supplementary Fig. 2g ). Together, these findings suggest that FAK activation in tumor cells might play a key role in establishing the immunosuppressive TME.
FAK inhibition leads to temporary tumor stasis and extended survival in KPC mice
To assess the impact of inhibiting FAK on PDAC progression, we evaluated a clinically available dual FAK1 and FAK2 inhibitor, VS-4718 (hereafter referred to as FAKi; Supplementary Fig. 3a ), in the genetic KPC and p48-Cre;LSL-Kras G12D ;Trp53 flox/flox (KPPC) mouse models. We evaluated both early and late therapeutic strategies by either treating KPC mice at 3.5 months of age, when over 90% of these mice have histological microscopic PDAC lesions (early), or when overt (palpable) and/or ultrasound-detectable (>0.5 cm in diameter) tumors were identified (late). We found that single-agent FAK inhibition caused a significant and similar extension of survival in both early and late treatment groups ( Fig. 2a) . These results are particularly notable in comparison with gemcitabine (GEM) treatment, a standard clinical npg a r t i c l e s treatment, which has no effect on survival in these models. A similar improvement of survival was observed in the extremely aggressive KPPC mouse model when mice bearing overt PDAC tumors were treated with FAKi ( Fig. 2b) . To assess whether single-agent FAK inhibition leads to tumor regression or tumor stasis, we evaluated KPC mice for gross tumor diameter by twice-weekly external caliper measurement. Using this approach, we observed that single-agent FAK inhibition increased survival by inducing prolonged tumor stasis rather than regression ( Fig. 2c) . Similar responses were seen in mice bearing orthotopic tumors derived from KI (Kras;INK4A) or KP (Kras;Trp53) cells treated with vehicle or FAKi ( Fig. 2d and Supplementary Fig. 3b ).
Taken together, these data indicate that FAK signaling is an important regulator of PDAC progression, consistent with its observed role in the pathogenesis of other types of cancer 25, 26, 31 .
Inhibition of FAK decreases fibrosis
To determine whether FAK inhibition affects the formation of the otherwise-abundant fibrosis in these tumors, PDAC tissue from endstage KPC and KPPC mice, as well as KPC mice treated for 1.5 months, was evaluated. We found that FAKi-treated KPC and KPPC mice had markedly reduced levels of fibrosis, as seen by both decreased collagen deposition (Trichrome and Sirius Red staining) and reduced numbers of fibroblasts expressing fibroblast activation protein alpha (FAP) and α-smooth muscle actin (α−SMA) compared with vehicle-treated mice ( Fig. 2e,f and Supplementary Fig. 3c-e ).
To better understand the mechanisms leading to decreased stromal density, we evaluated both tumor and stromal proliferation on the basis of Ki67 staining. We found that even in end-stage KPC and KPPC tumors, PDAC tumor cell proliferation was decreased by 43% in FAKi-treated mice. More notably, PDAC stromal cell proliferation was markedly decreased by up to 87% following FAK inhibition in both KPC and KPPC mice ( Fig. 2g and Supplementary Fig. 3f ). This stromal proliferation primarily localized to FAP + fibroblasts, as observed by IHC (Fig. 2h) . In addition, expression profiling of PDAC tissue from animals treated with FAKi revealed downregulation of multiple genes associated with fibrosis, collagen deposition and remodeling ( Fig. 2i and Supplementary Table 1 ). Taken together, these data suggest that FAK inhibition enhances survival by inducing PDAC tumor stasis while simultaneously inducing stromal depletion.
Inhibition of FAK decreases fibrosis without accelerating tumor progression
Recent studies have suggested that depletion of stromal fibrosis has the potential to lead to disease acceleration and more aggressive tumors 9, 32 . To assess how stromal depletion by FAKi affects the differentiation and aggressiveness of PDAC tumors, we analyzed pancreatic tumor tissue from end-stage KPC and KPPC animals for tumor stage and grade. We found that, in concert with longer survival, tissue from FAKi-treated KPC mice had a decreased pathologic disease progression when compared with that of vehicle-treated mice ( Fig. 3a and Supplementary Fig. 3g ). KPPC mice also showed no evidence of disease acceleration (Supplementary Fig. 3h ).
As discussed above, FAK signaling has been implicated in tumor invasion, which might explain the suppressed tumor progression observed in KPC mice. To assess this behavior, we used KPC-YFP mice treated at 3.5 months of age with vehicle or FAKi for 1 month and quantified individual invading cells, a hallmark of tumor aggressiveness in this model 33 . We observed significantly reduced numbers of single YFP + invasive tumor cells ( Fig. 3b) . In correlation with our results from KPC-YFP mice, a short 10-d treatment of mice bearing established orthotopically implanted PDAC tumors with FAKi decreased the frequency of ALDH Bright and CD44 Hi CD24 Hi tumor cells, indicating a potential reduction in tumor-initiating cells ( Fig. 3c) 34, 35 . Furthermore, we found less liver metastasis in KPC mice treated with FAKi ( Fig. 3d) . Taken together, these data suggest that FAK inhibition diminishes tumor-induced fibrosis, but, unlike recent reports 9,32 , reduces disease progression.
Inhibition of FAK decreases immunosuppressive cell populations in tumors
To explore how FAK inhibition might affect immunosuppressive cell populations in PDAC tissue, we analyzed tumor-infiltrating immune cells in KPC mice treated for 1.5 months with vehicle or FAKi. IHC analysis of PDAC tissue showed significantly fewer tumorinfiltrating F4/80 + and CD206 + macrophages and GR1 + granulocytes in FAKi-treated KPC mice (Fig. 4a) . Consistent with reduced infiltration of suppressive myeloid cell populations, we also observed decreased tumor cell p-STAT3 expression in PDAC tissue ( Fig. 4b) , suggesting a potential signaling mechanism for FAKi effects on npg immunosuppressive cell infiltration. To confirm these results and to eliminate effects resulting from differing tumor stages, we analyzed mice bearing established orthotopic KI or KP tumors by flow cytometry. We found that, following 10 d of FAKi treatment, the numbers of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), CD206 + tumor-associated macrophages (TAMs) and CD4 + FOXP3 + regulatory T cells (T regs ) were decreased ( Fig. 4c and Supplementary  Fig. 4a,b) .
To verify that these changes in tumor-infiltrating immunosuppressive cells were not a result of alterations in myelopoiesis, we analyzed bone marrow and blood from mice bearing established KP tumors that were treated for 10 d with FAKi (as described above). During this time period, we observed no change in bone marrow or circulating monocytes, granulocytes, dendritic cells or their precursor populations (Supplementary Fig. 5a-c) . Together, these data suggest that pharmacologic FAK inhibition dampens immunosuppressive inflammatory cell infiltration into PDAC tumors.
Neoplastic cell-intrinsic FAK promotes tumor protective fibrotic and immunosuppressive TME FAK activity has been implicated in the biologic activity of both neoplastic cells and stromal cells, including endothelial cells, fibroblasts and leukocytes 14, 25, 36 . These data suggest that FAK is directly involved with both tumor and stromal compartments. The roles of each of these compartments likely contribute to the overall outcome of pharmacologic inhibitors studies. On the basis of our observation that high p-FAK1 levels in the neoplastic cells in human PDACs correlated with fibrosis and inflammatory cell infiltration, we hypothesized that FAK1 activity in tumor cells might be a critical driver of the immunosuppressive PDAC TME. To test this, we knocked down FAK1 in PDAC cells derived from either KPC mice (KP cells) or p48-Cre/LSL-Kras G12D mice (KC cells; Supplementary Fig. 6a ). Perhaps surprisingly, knockdown or pharmacologic inhibition of FAK1 did not suffice to alter cell proliferation in vitro under threedimensional culture conditions (Fig. 5a) . Notably, concomitant pharmacologic inhibition of both FAK1 and FAK2/PYK2 (FAK1/2i) did indeed succeed in suppressing cell proliferation, suggesting that FAK1 is either dispensable for cell proliferation or compensated for by FAK2/PYK2 expression ( Fig. 5a and Supplementary Fig. 6a,b) .
In contrast with these in vitro results, loss of FAK1 alone significantly retarded growth of both KP and KC cells when implanted in syngeneic immune-competent hosts ( Fig. 5b and Supplementary  Fig. 6c ). Because of these differences in in vitro and in vivo growth, we postulated that FAK1-deficient cells failed to create a tumorsupportive TME. To test this notion, we analyzed similarly sizematched subcutaneous tumors and short-term orthotopic grafts derived from either shLuc or shFAK1 KP cells. In both settings, we found that reduction of FAK1 expression in the carcinoma cells retarded tumor-induced collagen deposition, FAP + fibroblast numbers and the presence of Ki67 + fibroblasts ( Fig. 5c and Supplementary  Fig. 6d,e ). In addition, FAK1-deficient tumors had reduced infiltration by MDSCs and CD206 + TAMs (Fig. 5d) . This reduction in immunosuppressive myeloid cells was accompanied by a marked increase in the numbers of infiltrating CD8 + CTLs (Fig. 5d) .
These data suggest that FAK1 is required for PDAC cells to create the fibrotic and immunosuppressive TME that protects the tumor from immune surveillance by CTLs. To further explore this notion, we depleted both CD4 + and CD8 + T cells using depleting IgG and found that, although a loss of T cells did not affect outgrowth of control shLuc-expressing KP-derived tumors, it did restore shFAK1-expressing KP tumor growth to control levels (Fig. 5e) . These findings, in combination with our observations in human tissues, suggest that tumor-intrinsic FAK1 drives the fibrotic and immunosuppressive TME that blunts T cell-mediated immune surveillance.
To understand more precisely how PDAC neoplastic cell-intrinsic FAK1 activity might drive inflammation and fibrosis, we profiled cytokine production from KP cells and found that FAK inhibition markedly reduced both pro-inflammatory and pro-fibrotic cytokine secretion ( Fig. 5f and Supplementary Fig. 6f ). We next sought to test whether these alterations in cytokine production would reduce the capacity of PDAC tumor cells to induce myeloid cell recruitment and/or pro-tumor polarization. First, we found that both genetic (shRNA) and pharmacologic inhibition of FAK1 signaling in KP cells npg a r t i c l e s impaired their ability to induce monocyte and granulocyte migration (Fig. 5g) . Second, we found that, although both murine and human PDAC cell lines were able to induce alternative activation of macrophages, as measured by elevated CD206 or CD163 protein expression and/or elevated ARG1, YM1 and CCL2 gene expression, this induction was blocked when PDAC cells were pre-treated with FAKi (Supplementary Fig. 6g-j) . These data suggest that hyper-activated FAK1 in PDAC neoplastic cells drives cytokine production, which in turn results in increased myeloid cell recruitment and pro-tumor polarization of macrophages. We next sought to more directly assess whether loss of FAK1 might directly affect the ability of PDAC cells to promote expansion of tumor-associated fibroblasts. We noted that the loss of FAK activity in PDAC cells reduced their production of pro-fibrotic factors, such as CCL6, CCL20 and CXCL12 ( Fig. 5f and Supplementary Fig. 6f ). We also found that direct co-culture or conditioned medium (CM) from KP or KC cells induced high levels of proliferation in normal pancreatic fibroblasts; however, CM from FAK1-deficient KP or KC cells failed to increase fibroblast proliferation ( Fig. 5h and Supplementary  Fig. 6k,l) . Notably, pharmacologic or genetic inhibition of FAK1 in cancer-associated fibroblasts sorted from KPPC mice did not inhibit cell proliferation in vitro (Supplementary Fig. 6m,n) . Neutralization of CXCL12 in CM from KP cells was sufficient to restrict the level of PDAC-induced fibroblast proliferation to basal levels equal to those of fibroblasts treated with CM from FAK1-depleated cells (Fig. 5i) . These data suggest that FAK1 activity in PDAC cells can drive stromal expansion in part by elevating CXCL12 production.
FAK inhibition renders previously unresponsive PDACs sensitive to chemo-and immunotherapy
Recent studies have shown that stromal depletion may facilitate responses to chemo-and immunotherapy in PDAC [9] [10] [11] 32 . In addition, excessive tumor infiltration of myeloid cells may further blunt the efficacy of both chemotherapy 4,13,37-41 and immunotherapy 2, 42, 43 . Given that FAK inhibition reduced both fibrosis and suppressive myeloid cells, we sought to test the ability of FAK inhibition to improve chemo-and immunotherapeutic efficacy. We first treated KPPC mice bearing overt tumors with either vehicle or high-dose GEM (75 mg per kg of body weight, intravenously (i.v.), GEM75) in the presence or absence of FAKi. Consistent with reported results 10, 32, 44 , we found that GEM75 treatment alone conferred no survival benefits in KPPC mice. In contrast, the combination of FAKi plus GEM75 more than doubled the median survival duration of the mice (Fig. 6a) . Furthermore, increased PDAC cell apoptosis and tumor necrosis, as well as reduced fibrosis, were observed in endstage mice ( Fig. 6b and Supplementary Fig. 7a) .
To assess the ability of FAK inhibition to improve immunotherapy by increasing T cell infiltration into tumors, we tested FAKi in combination with adoptive T cell transfer (ACT). To evaluate this, we established syngeneic tumors with KP cells expressing chicken ovalbumin (OVA), a potent T cell antigen. We next injected transgenic CD8 + T cells specific for OVA that also expressed CD45. npg a r t i c l e s although ACT alone modestly slowed tumor progression, treatment with FAKi and ACT abrogated tumor growth ( Fig. 6c) . To determine whether the increased efficacy of ACT following FAKi treatment was a result of the increased ability of T cells to infiltrate PDAC tumors, we assessed both circulating and tumor-infiltrating OT-I T cell numbers using flow cytometry and bioluminescent imaging (BLI). We found that, although the number of circulating CD45.1 + OT-I cells was unchanged by FAKi treatment (Supplementary Fig. 7b) , FAKi treatment still resulted in 4.7-fold more OT-I cells infiltrating into PDAC tumor tissue compared with vehicle-treated mice (Fig. 6d) . Together, these data suggest that FAKi alters the TME to facilitate CTL infiltration and/or survival in the PDAC TME.
To further test the ability of FAKi to improve immunotherapy, we evaluated several combinations of checkpoint immunotherapies with FAKi in syngeneic and genetic PDAC models. Using both syngeneic and orthotopic models, we found that FAK inhibition promoted the responsiveness to a PD-1 antagonist (anti-PD1), as seen by reduced tumor burden and improved overall survival; however, the maximum effect was seen when given in combination with low-dose GEM (25 mg/kg i.v., GEM25; Fig. 6e and Supplementary Fig. 7c ). We also found that mice bearing transplantable KP tumors that were treated with FAKi + GEM25 + anti-PD1 had a significantly increased number of tumor-infiltrating CD8 + CTLs compared with vehicle + GEM25 + anti-PD1 treated mice (Fig. 6f) . Notably, FAKi did not improve the responsiveness to anti-CTLA4 alone, but anti-CTLA4 did show added benefit when added to FAKi + GEM25 + anti-PD1 therapies (Supplementary Fig. 7d,e) .
We next sought to test FAKi plus immunotherapy in the KPPC transgenic mice, as this mouse model recapitulates the poor immunogenicity and rapid progression typical of human pancreatic cancer. Treatment of KPPC mice with GEM25 + anti-PD1 + anti-CTLA4 (Immuno) did not alter survival compared to vehicle-treated mice, suggesting that KPPC mice had little de novo responsiveness to checkpoint immunotherapy. By contrast, KPPC mice treated with FAKi + GEM25 + anti-PD1/anti-CTLA4 showed a greater than 2.5-fold increase in median survival time, with a subset of mice (2 of 15) still alive 6 months after the start of treatment (Fig. 6g) . This observed improvement in immunotherapeutic efficacy was associated with increased numbers of CD8 + CTLs that penetrated the stroma and came into close proximity and/or contact with target CK19 + PDAC cells; at the same time, these tumors exhibited reduced numbers of CD4 + FOXP3 + T regs , and better T effector (T eff ) to T reg ratios in the tumors ( Fig. 6h and Supplementary Fig. 7f ). Taken together, these data indicate that FAK inhibition, which diminished the fibrotic and immunosuppressive TME, can render previously unresponsive PDAC tumors responsive to chemo-and immunotherapy.
DISCUSSION
We found that FAK signaling is a key driver of fibrosis, immunosuppression and PDAC progression. Several FAK inhibitors are in clinical testing now; to date, however, FAK inhibitors as single agents have failed to induce tumor regression in advanced cancer patients. Our own data in murine PDAC models agree with this, as we observed disease stabilization rather than PDAC regression in KPC mice (Fig. 2c) . These data are consistent with results from the completed phase I study of single agent FAK inhibition (VS-6063/PF-00562271) in patients with advanced solid tumors, NCT00787033. In this study, 43% (16 of 37) of patients enrolled at doses >100 mg experienced stable disease. One of these patients had PDAC and had stable disease on single-agent FAK inhibition for >6 months. These clinical data suggest that FAKi combination therapies may be important for achieving durable tumor regression in advanced cancer patients. In our hands, pharmacologic or genetic targeting of FAK augmented tumor immunity, and thereby potentiated the efficacy of chemo-and immunotherapy, even in PDAC tumors that were previously unresponsive to these therapies. Our data strongly support the translation of FAK inhibitors in combination with checkpoint immunotherapy, an approach that is currently undergoing clinical trials (NCT02546531).
Given that many FAK inhibitors, including the one we employed, are active against both FAK1 and FAK2/PYK2, it is important to consider the roles of each of these kinases. We found that FAK1 in PDAC cells can be a driver of tumor-induced fibrosis and immune suppression (Fig. 5) . However, this does not exclude a potentially critical role of FAK2/PYK2 in regulating fibrosis and/or immune suppression in response to dual FAK1-PYK2 inhibitors, such as VS-4718 or others undergoing clinical trials. We found that both FAK2/PYK2 and phospho-PYK2 were elevated in human and murine PDACs (Supplementary Fig. 1f,g) . In addition, PYK2 has been shown to be important in wound healing, fibrosis, and myeloid cell migration and differentiation [19] [20] [21] [22] [23] [24] . Thus, a further dissection of the exact contribution of both FAK1 and PYK2 in driving fibrotic and immunosuppressive TMEs will be critical to exploiting FAK inhibition to benefit cancer patients.
We focused on the role of FAK1 signaling in malignant cells and its role as a driver of the fibrotic and inflammatory TME that thwarts immune surveillance and limits immunotherapy. However, clinical use of FAK inhibitors will target all cell types, including T cells themselves [45] [46] [47] [48] . Both FAK1 and PYK2 are activated downstream of both T cell receptor and co-stimulatory signaling, and have been shown to be involved in T cell proliferation, antigen sensitivity, cytokine production and migration in these contexts (reviewed in ref. 47) . We found no alterations in total circulating T cells or transferred antigen-specific T cell numbers following pharmacologic inhibition of FAK1 and PYK2; however, the effect of such treatments on T cell functionality is likely important to clinical translation of FAK inhibitor and immunotherapeutic combinations.
FAK signaling has been confirmed as a regulator of multiple signaling pathways during tumor progression, including cell-cell adhesion, migration, proliferation and chemokine transcription 14 . As such, FAK1 has been shown to be important in several carcinoma types, including pancreatic tumors 14, 26, [49] [50] [51] [52] [53] . However, the role of FAK signaling in driving the suppressive tumor microenvironment is less well understood. A recent study in squamous carcinoma mouse models found that nuclear FAK1 in carcinoma cells drives exhaustion of CD8 + T cells and recruitment of T regs to the TME by altering chemokine/cytokine networks 15 . Similarly, we found that FAK inhibition altered tumor cell production of pro-inflammatory and immunosuppressive cytokines and blunted their ability to avoid immune surveillance. Together, these findings indicate that FAK1 signaling may be a key driver of immune escape in several tumor types, and thus may be a target for combination with immunotherapy.
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